GLP-1 Medication – Semaglutide (Ozempic) -

Semaglutide is a glucagon-like peptide (GLP-1) analog approved in 2017 as a treatment method for improving glycemic control in patients with Type 2 diabetes. Semaglutide shows great promise for patients who are having difficulty losing weight. Studies have demonstrated that Semaglutide reduced appetite, improved control of eating, and reduced food cravings in addition to improved glycemic control. The greatest weight loss benefits were observed when Semaglutide is used in combination with lifestyle changes, such as improved diet and consistent exercise.

Get Started

Weight Loss Benefits

Approximately 70% of American adults are overweight or obese. Serious health issues are associated with being overweight or obese including heart disease, stroke and diabetes, and is linked to an increased risk of certain types of cancer. Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adult patients with obesity or overweight.

Appetite Control & Reduced Food Cravings

Weight Loss

Improved Glycemic Control

How to Use

Semaglutide is a subcutaneous injection which is dosed once weekly. This medication is generally well-tolerated and can be dosed continuously without breaking treatment with no diminishing effects.

Precautions & Side Effects

The most commonly reported side effects include nausea, diarrhea, vomiting, constipation, and stomach pain. The risk of serious side effects increases in patients with hypoglycemia, kidney problems, and risk of allergic reactions. This medication is NOT an insulin and should not be used if you have type 1 diabetes or if you develop diabetic ketoacidosis. The prescribing information for Semaglutide contains a boxed warning to inform healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Semaglutide should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

  • Nausea - Can be prevented or decreased with prescribed anti-nausea medication if needed.
  • Diarrhea
  • Constipation
  • Vomiting
  • Abdominal pain